Citation Impact
Citing Papers
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
2013 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
2013
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus
2011
Glitazones and the management of insulin resistance: what they do and how might they be used
2004
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
2009 Standout
Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials
2008
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
2007
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
2013
The metabolic syndrome
2010 Standout
Adjustable Gastric Banding and Conventional Therapy for Type 2 Diabetes
2008
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
2017 Standout
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
The biology of incretin hormones
2006 Standout
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
2007 Standout
Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program
2011
Type 2 diabetes as an inflammatory disease
2011 Standout
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
2006
The role of gut hormones in glucose homeostasis
2007
The metabolic syndrome
2005 Standout
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
2006 Standout
Biology of Incretins: GLP-1 and GIP
2007 Standout
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
2012
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2012
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
2014 Standout
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
2015 Standout
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Type 2 diabetes
2017 Standout
Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy
2003
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
2015 Standout
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
2012 Standout
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly
2008
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
2008
The Physiology of Glucagon-like Peptide 1
2007 Standout
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
2008 Standout
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B–containing lipoproteins
2008 StandoutNobel
Treatment of active psoriatic arthritis with the PPAR ligand pioglitazone: an open-label pilot study
2004
Efficacy of berberine in patients with type 2 diabetes mellitus
2008 Standout
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
2007
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Prediabetes: a high-risk state for diabetes development
2012 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis
2007
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Fluorine in medicinal chemistry
2007 Standout
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
2013 Standout
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
2008 Standout
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Fat and Beyond: The Diverse Biology of PPARγ
2008 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Preparation of Porous Polysaccharides Templated by Coordination Polymer with Three-Dimensional Nanochannels
2017 StandoutNobel
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Thiazolidinedione safety
2012
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
2007
Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1
2007
Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease
2006
Mechanisms of Diabetic Complications
2013 Standout
Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
2008
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
2005
New Drugs for the Treatment of Diabetes
2008
Lipids and Lipoproteins in Patients With Type 2 Diabetes
2004
Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications
2004
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
2006
Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
2013
Works of Don Johns being referenced
Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis
1999
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
2008
Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes
2003
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens
2005
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
2006
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial
2004
Long‐term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus
2005
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
2007
Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes
2004
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
2003
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes
2005
Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents
2007
Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 Diabetes
2005
Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes
2005